NCT04853498View on ClinicalTrials.gov

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

PHASE1UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 19, 2021

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

TQB3720

This is an androgen receptor antagonists.

Trial Locations (1)

200035

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY